Cargando…

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes

SIMPLE SUMMARY: Non-small cell lung cancer (NSCLC) patients harboring BRAF non-V600 alterations constitute a heterogeneous and poorly studied population orphan of targeted therapies. We conducted a systematic review to detect all BRAF alterations of defined functional class across different cancer t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Di Federico, Alessandro, De Giglio, Andrea, Gelsomino, Francesco, De Biase, Dario, Giunchi, Francesca, Palladini, Arianna, Sperandi, Francesca, Melotti, Barbara, Ardizzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319412/ https://www.ncbi.nlm.nih.gov/pubmed/35884534 http://dx.doi.org/10.3390/cancers14143472

Ejemplares similares

Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
por: De Giglio, Andrea, et al.
Publicado: (2022)

The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
por: De Giglio, Andrea, et al.
Publicado: (2022)

The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
por: Comito, Francesca, et al.
Publicado: (2022)

EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
por: Di Federico, Alessandro, et al.
Publicado: (2022)

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
por: Lamberti, Giuseppe, et al.
Publicado: (2020)

BRAF‐mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis
por: Abbati, Francesca, et al.
Publicado: (2021)

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
por: Parisi, Claudia, et al.
Publicado: (2020)

Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation
por: Caliò, Anna, et al.
Publicado: (2016)

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
por: Gelsomino, Francesco, et al.
Publicado: (2021)

IFN-γ and CD38 in Hyperprogressive Cancer Development
por: Angelicola, Stefania, et al.
Publicado: (2021)

Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
por: Di Federico, Alessandro, et al.
Publicado: (2021)

ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
por: Ruzzi, Francesca, et al.
Publicado: (2022)

Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
por: Sisi, Monia, et al.
Publicado: (2022)

Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study
por: Ricci, Costantino, et al.
Publicado: (2020)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Gastrointestinal Goblet Cell Adenocarcinomas Harbor Distinctive Clinicopathological, Immune, and Genomic Landscape
por: Lin, Dong-Liang, et al.
Publicado: (2021)

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
por: Obaid, Nourah Mohammad, et al.
Publicado: (2017)

Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2020)

Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
por: Gelsomino, Francesco, et al.
Publicado: (2021)

Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance
por: Kim, Namkyoung, et al.
Publicado: (2021)

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights
por: Caputo, Francesco, et al.
Publicado: (2019)

Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT
por: Ricci, Costantino, et al.
Publicado: (2023)

The landscape of BRAF transcript and protein variants in human cancer
por: Marranci, Andrea, et al.
Publicado: (2017)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020)

Peripheral nervous system adverse events associated with immune checkpoint inhibitors
por: Rossi, Simone, et al.
Publicado: (2023)

Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups
por: Perrone, Fabiana, et al.
Publicado: (2022)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
por: Dall’Olio, Filippo G., et al.
Publicado: (2020)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
por: Chen, Yungchang, et al.
Publicado: (2023)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

MENINGES HARBOR IMMUNE MEMORIES OF LIFE EXPERIENCES
por: Herz, Jasmin, et al.
Publicado: (2022)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study
por: Lastraioli, Elena, et al.
Publicado: (2022)

Cutaneous and Mucosal Melanomas of Uncommon Sites: Where Do We Stand Now?
por: Dika, Emi, et al.
Publicado: (2021)

Mutant BRAF in low-grade epilepsy-associated tumors and focal cortical dysplasia
por: Marucci, Gianluca, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_85ms9p07ttmn36m3krdsu16c2i